Sort
48,018 grants matching “immunotherapy”
Neuronal and glial interactions of neuropathic pain
$488,534William Maixner · Duke University · R01 · FY2019 · DE
Neuronal and glial interactions of neuropathic pain
$488,534Thomas Buchheit · Duke University · R01 · FY2021 · DE
GENETICALLY ENGINEERED T CELLS FOR DIPG
$488,517Giedre Krenciute · St. Jude Children'S Research Hospital · R01 · FY2024 · NS
Defining Mechanisms of Progression and Treatment Resistance in Localized Bladder Cancer
$488,477Eugene Pietzak · Sloan-Kettering Inst Can Research · R37 · FY2024 · CA
Targeting the innate immune response in HNSCC
$488,418Judith A. Varner · University Of California, San Diego · R01 · FY2024 · DE
Overcoming vaccine-associated hypoxia with advanced biomaterials to enhance cancer immunotherapy
$488,344Sidi A Bencherif · Northeastern University · R01 · FY2021 · EB
PD-1/PD-L1 modulation in cancer therapy
$488,332Drew M. Pardoll · Johns Hopkins University · R01 · FY2017 · CA
PD-1/PD-L1 modulation in cancer therapy
$488,332Drew M. Pardoll · Johns Hopkins University · R01 · FY2016 · CA
PD-1/PD-L1 modulation in cancer therapy
$488,332Drew M. Pardoll · Johns Hopkins University · R01 · FY2018 · CA
Innate Immunity to Spiral Ganglion Neuron Degeneration
$488,314Tejbeer Kaur · Rutgers Biomedical And Health Sciences · R01 · FY2023 · DC
Mechanistic studies of gut microbiota-mediated immune activation against hepatocellular cancer
$488,308Kevin Finnbar Staveleyo'carroll · University Of Connecticut Sch Of Med/Dnt · R01 · FY2025 · CA
Lineage heterogeneity and plasticity in lung cancer
$488,292Hideo Watanabe · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · CA
Development of SUV39H1-selective inhibitor for human colon cancer therapy
$488,240Kebin Liu · Augusta University · R01 · FY2025 · CA
The role of sex in the life cycle and transmission of Pneumocystis
$488,236Melanie T Cushion · University Of Cincinnati · R01 · FY2022 · HL
Systems Biology of Antigen and T-Cell Transport in Cancer Immunotherapy
$488,228Timothy P Padera · Massachusetts General Hospital · R01 · FY2025 · CA
Targeting Negative Regulatory Pathways for Immunotherapy of B-Cell Lymphomas
$488,216Eduardo M Sotomayor · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2010 · CA
NIH Myeloid Malignancy Program
$488,202Steven Pavletic · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Development of novel AAV vaccine strategy in a pre-clinical model of oral melanoma.
$488,155George V Aslanidi · University Of Minnesota · R01 · FY2025 · CA
Rapid and flexible precision oncology mouse models of epithelial malignancies epithelial malignancies
$488,090Scott W Lowe · Sloan-Kettering Inst Can Research · R01 · FY2021 · CA
Rapid and flexible precision oncology mouse models of epithelial malignancies epithelial malignancies
$488,090Scott W Lowe · Sloan-Kettering Inst Can Research · R01 · FY2020 · CA
Role of microbially-derived metabolites in anti-tumor immunity in breast cancer
$488,057Liza Makowski Hayes · University Of Tennessee Health Sci Ctr · R01 · FY2025 · CA
Characterizing and Targeting BAX- and BAK-Dependent Cell Death in Cancer
$487,929Emily H Cheng · Sloan-Kettering Inst Can Research · R01 · FY2024 · CA
Project 2: Druggable dependencies in diffuse midline gliomas
$487,885Daphne A. Haas-Kogan · Brigham And Women'S Hospital · P50 · FY2024 · CA
Project 1: Evaluating stem-like T cells and improving efficacy of checkpoint inhibitors in NSCLC
$487,846Rafi Ahmed · Emory University · P50 · FY2021 · CA
Immunochemotherapy in Visceral Leishmaniasis
$487,832Henry W. Murray · Weill Medical Coll Of Cornell Univ · R01 · FY2010 · AI